A Multicenter Study with a Randomized, Double-Blind,Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis.

Eli Lilly Japan K.K.0 个研究点目标入组 33 人开始时间: 2012年8月30日最近更新: 2023年10月17日

研究概览

暂无简介。

研究类型: Interventional
分配方式: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

•This study will enroll male or female patients aged 18 years or older who have chronic plaque Ps based on a confirmed diagnosis of chronic Ps vulgaris for at least 6 months who are candidates for phototherapy and/or systemic therapy, and who have more than 10% BSA involvement, an sPGA score of more than 3, and a PASI score more than 12 at screening and baseline.

•-Pustular, erythrodermic, and/or guttate forms of psoriasis
•-History of drug-induced psoriasis
•-Clinically significant flare of psoriasis during the 12 weeks prior to randomization
•-Concurrent or recent use of any biologic agent
•-Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization
•-Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study
•-Have participated in any study with interleukin (IL)-17 antagonists, including LY2439821
•-Serious disorder or illness other than plaque psoriasis
•-Serious infection within the last 3 months
•-B19Breastfeeding or nursing (lactating) women.

发起方